Hoffmann-la Roche Inc.

Roche Glycart Ag

Genentech, Inc.

Roche Palo Alto LLC

Hoffman-laroche, Inc. (us Only)

F. Hoffman-laroche, Ag (ex-us)

F. Hoffmann-la Roche Ag

Matthias Rueth

Edgar Voss

Walter-Gunar Friebe

Birgit Bossenmaier

Ulrike Reiff

Bernhard Goller

Guy Georges

Joerg Thomas Regula

Petra Rueger

Thomas Friess

Christian Klein

Kay-Gunnar Stubenrauch

Anja Limberg

Klaus-Peter Kuenkele

Frank Herting

Harald Duerr

Bing-Yan Zhu

Frederick Arthur Brookfield

David Michael Goldstein

Wolfgang Schaefer

Jun Liang

Brian Salvatore Safina

Edward Andrew Boyd

Stefan Scheiblich

Wolfgang Von Der Saal

Tilman Schlothauer

Hans-Willi Krell

Birong Zhang

Guido Hartmann

Lothar Kling

Stefan Weigand

Thomas E Rawson

Aihe Zhou

Jun M Li

Jennafer Dotson

Ignacio Aliagas-Martin

Wolfgang Jenni

Jason S Halladay

Justin Warne

Christine Schuell

Michael Prime

Frederick Brookfield

Aude Lemarchand

Georges Guy

Sabine Huensch

Herein is reported the use of an antibody comprising an Fc-region with abolished FcRn binding for the transport of a soluble receptor ligand from the eye over the blood-ocular-barrier into the blood circulation.

Human FcRn-binding modified antibodies and methods of use

The present invention relates to bispecific antibody against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2) of human IgG1 or IgG4 subclass with mutations I253A, H310A, and H435A, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases

The invention provides novel kinase inhibitors that are useful as therapeutic agents for example in the treatment malignancies where the compounds have the general formula I wherein A, X, Y, Z, Ra, Rb, Rc, R, R, Rand m are defined herein.

Pentacyclic kinase inhibitors

Methods of inhibiting a tyrosine kinase wherein said tyrosine kinase is BTK or SYK comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to formula I are disclosed. The compounds are useful for treating auto-immune and inflammatory diseases. 

Methods of inhibiting BTK and SYK protein kinases

The present invention relates to the compounds of formula I: their pharmaceutically acceptable salts or esters, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, pharmaceutical compositions containing them and their manufacture, as well as the use of such compounds in the control or prevention of illnesses such as cancer.

Aminopyrazole derivatives

The present invention provides the compounds of formula I their pharmaceutically acceptable salts or esters, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, pharmaceutical compositions containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.

Oxidized thioether derivatives

The present invention relates to the compounds of formula I: their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, compositions containing such compounds and their manufacture, as well as the use of such compounds in the control or prevention of illnesses such as cancer.

Indole derivatives

The present invention relates to compounds of formula I their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.

Tricycles, their manufacture and use as pharmaceutical agents

There are presented compounds of formula (I) their pharmaceutically acceptable salts, enantiomeric forms thereof, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.

Arylazole derivatives, their manufacture and use as pharmaceutical agents

The present invention relates to novel oxazoles of formula (I) their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.

Oxazoles, their manufacture and use as pharmaceutical agents

The present invention provides the compounds of formula I-A their pharmaceutically acceptable salts or esters, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, pharmaceutical compositions containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.

Pentafluorosulfanyl compounds

Compounds of formula I their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates are disclosed. Also disclosed are methods for the preparation of the above-mentioned compounds, pharmaceutical compositions containing them, as well as the use of the above-mentioned compounds in the treatment, control or prevention of illnesses such as cancer.

Phthalazinone derivatives

Compounds of formula (I) are useful in the therapy and/or prevention of illnesses with known over-expression of receptor tyrosine kinases of the HER-family like HER-2 and EGFR (HER-1). Accordingly, these compounds are useful for the treatment of diseases such as cancer in humans or animals.

Aniline derivatives, their manufacture and use as pharmaceutical agents

The present invention 1 includes compounds of formula (I), and their pharmaceutically acceptable salts. These compounds are useful in the control or prevention of cancer.

Oxazole derivatives

Growing community of inventors

Penzberg, Germany

Matthias Rueth